Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutatuion positive melanoma(BRIM-3): extended follow up of phase 3 randimised open label study

Abstract

In the BRIM-3 trial, vemurafenib was associated with risk reduction versus dacarbazine of both death and progression in patients with advanced BRAFV600 mutation-positive melanoma. In this publication is presented an extended follow-up analysis of the total population and in the BRAFV600E and BRAFV600K mutation subgroups.

Keywords

• Metastatic melanom
• BRAF mutations
• vemurafenib
• adverse events